Riva Alessandro sold 212 shares of BeOne Medicines Ltd. at $309.51 for −$65.6k on May 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed May 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$65,617.01Shares × reported price
Shares traded
212American Depositary Shares
Price per share
$309.51Reported price. Read footnotes for ranges.
% of reported position traded
100%This security and ownership context
Holdings after
0Direct
Trade date
May 22, 2026Sell
Filed
May 27, 2026, 5:29 PM ET5-day reporting delay
Accession
0001867172-26-000004Code S · Transaction 88423
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 212 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ONC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ONC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +4.1%1w ago −2.2%1d ago +3.2%
Returns since7d −7%30d −6.7%90d +26%180d1y

Footnotes in full

F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.